Balanced news tone
News Sentiment
CMPSN sentiment intelligence
COMPASS PATHWAYS PLC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
57
Balanced news tone
19 relevant articles
News tone and price action are not far from neutral.
78/100 classification confidence.
directly relevant articles
high-authority source matches
+0.0% over one week, +65.8% over four weeks, trend active, and materially above fair value.
Why is Compass Pathways stock being clobbered today?
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Analyst action
78/100 classification
One-week reaction
0.0%
Price digesting
Trend fit
Trend active
65.8% over four weeks
Fair value
125.0%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
9
Neutral
9
Negative
1
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Investing.com
Direct company coverage
Why is Compass Pathways stock being clobbered today?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jun 2026 07:00
- Source
- Investing.com
Investing.com
Direct company coverage
Compass Pathways stock rating reaffirmed at Buy by TD Cowen
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 01 Jun 2026 07:00
- Source
- Investing.com
Investing.com
Direct company coverage
Why is Compass Pathways stock surging 9% today?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 07:00
- Source
- Investing.com
Investing.com
Direct company coverage
Compass Pathways stock hits 52-week high at 12.48 USD
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- Investing.com
Investing.com
Direct company coverage
Wolfe Research initiates Compass Pathways stock with outperform rating
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 22 May 2026 07:00
- Source
- Investing.com
Investing.com India
Direct company coverage
H.C. Wainwright reiterates Compass Pathways stock rating on FDA progress By Investing.com
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 22 May 2026 07:00
- Source
- Investing.com India
Investing.com
Direct company coverage
Why is Compass Pathways stock surging today?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 May 2026 07:00
- Source
- Investing.com
Investing.com
Direct company coverage
Compass Pathways stock maintained at Buy by TD Cowen on NDA progress
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 13 May 2026 07:00
- Source
- Investing.com
Investing.com
Direct company coverage
Why is Compass Pathways stock rallying today?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 May 2026 07:00
- Source
- Investing.com
Investing.com
Direct company coverage
B.Riley initiates Compass Pathways stock with buy rating, $17 target
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 24 Apr 2026 07:00
- Source
- Investing.com
Investing.com
Direct company coverage
Oppenheimer reiterates Compass Pathways stock rating on FDA review
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 24 Apr 2026 07:00
- Source
- Investing.com
Barchart.com
Direct company coverage
Trump Sends Compass Pathways Stock Soaring as He Backs Psychedelics. Should You Buy CMPS Here?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 20 Apr 2026 07:00
- Source
- Barchart.com
Investing.com
Direct company coverage
Morgan Stanley cuts Compass Pathways stock price target on TRD progress
- Tone
- Negative 34/100
- Event
- Analyst action
- Published
- 24 Mar 2026 07:00
- Source
- Investing.com
Investing.com
Direct company coverage
Compass Pathways stock price target raised to $22 by RBC Capital
- Tone
- Positive 64/100
- Event
- Analyst action
- Published
- 18 Feb 2026 08:00
- Source
- Investing.com
Clinical Trials Arena
Direct company coverage
Compass stock heads north on psychedelic’s Phase III TRD success
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Feb 2026 08:00
- Source
- Clinical Trials Arena
Investing.com
Direct company coverage
Compass Pathways stock soars after positive Phase 3 trial results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 17 Feb 2026 08:00
- Source
- Investing.com
Investing.com
Direct company coverage
Compass Pathways stock rating reiterated at Overweight by Cantor Fitzgerald
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 08 Jan 2026 08:00
- Source
- Investing.com
Investing.com
Direct company coverage
Oppenheimer upgrades Compass Pathways stock to Outperform on FDA pathway
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 09 Dec 2025 08:00
- Source
- Investing.com
Clinical Trials Arena
Direct company coverage
Compass’ stock slips despite psilocybin trial hitting target
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 24 Jun 2025 07:00
- Source
- Clinical Trials Arena